Gossamer Bio

Historical price data

Gossamer Bio is a clinical-stage biotech company dedicated to developing transformative therapies for rare diseases, currently centered on its lead asset, seralutinib, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's strategy leverages a novel inhaled delivery mechanism to target key disease pathways directly in the lungs. Having advanced seralutinib into pivotal Phase 3 trials, Gossamer represents a high-conviction, binary investment opportunity where near-term value creation is entirely dependent on the clinical and regulatory success of this single program.

Targeted inhaled delivery of a small molecule tyrosine kinase inhibitor (TKI) designed to maximize lung exposure and minimize systemic side effects.

In PAH, competes against established vasodilators and novel agents like Merck's sotatercept. In PH-ILD, faces an open field with no approved therapies, offering a first-mover opportunity if successful.